The Paris-headquartered ERYTECH Pharma S.A. is looking to submit eryaspase to the US Food and Drug Administration in the fourth quarter for hypersensitive acute lymphoblastic leukemia (ALL). This represents a turnaround for the company which had originally filed the product for ALL in the EU before pulling the submission three years ago after deciding that solid tumors, particularly pancreatic cancer, represented the best way forward for the compound. (Also see "Erytech Pulls Graspa ALL Filing To Focus On Pancreatic Cancer" - Scrip, 25 June, 2018.)
12 Key Oncology Drug Launches Expected In 2022 – Hematological Malignancies
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.
More from New Products
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.